Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | THRA | P10827 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 4/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083170 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL16672058 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL10574043 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL10415403 | 0.94 | ALDH1A1 (0.70) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL9805743 | 0.88 | CYP1A2 (0.81) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL9805821 | 0.88 | CYP1A2 (0.81) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL9805771 | 0.88 | THRA (0.56) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL11465372 | 0.88 | CYP2C19 (0.74) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL6344166 | 0.87 | THRA (0.55) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL6340900 | 0.87 | THRA (0.55) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-7323483-B2 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323483-B2 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1856104-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060183917-A1 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006081455-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | disclosed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1397356-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2003000684-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | SERPINE1, SERPINB1, TFPI | ALDH1A1 214/4885CYP1A2 43/4885HPGD 123/4885 |
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, F12 | ALDH1A1 871/4885CYP1A2 1235/4885HPGD 2039/4885 |
| US-20060183917-A1 | Processes and compounds for the preparation of substituted naphthylindole derivatives | SERPINE1, SERPINB1, TFPI | ALDH1A1 214/4885CYP1A2 43/4885HPGD 123/4885 |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | TFPI, SERPINE1, F12 | ALDH1A1 897/4885CYP1A2 1282/4885HPGD 1899/4885 |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | ALDH1A1 837/4885CYP1A2 1205/4885HPGD 1735/4885 |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | ALDH1A1 818/4885CYP1A2 1194/4885HPGD 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.